China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA) has approved its injectable bispecific antibody (BsAb) JS203 for a clinical study in relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The drug targets CD20 and CD3, leveraging these antigens to enhance tumor-inhibiting effects.
Drug Profile
- CD20: A key therapeutic target for B-cell lymphoma, expressed on B lymphocytes.
- CD3: A T-cell surface marker, critical for directing T cells to attack tumor cells.
- Preclinical Data: JS203 demonstrated significant tumor inhibition and good tolerability in animal studies.
Market Context
Globally, only one CD20/CD3 BsAb is commercially available—Roche’s Lunsumio (mosunetuzumab)—approved in the EU for relapsed/refractory follicular lymphoma (FL) patients who have received at least two prior therapies. No similar product is marketed in China.-Fineline Info & Tech
